Datasheet for ABIN2018387

FAM19A2 Protein

Go to Product page

Overview

Quantity:	1 mg
Target:	FAM19A2
Origin:	Human
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active

Product Details

Sequence:	ANHHKAHHVK TGTCEVVALH RCCNKNKIEE RSQTVKCSCF PGQVAGTTRA APSCVDASIV EQKWWCHMQP CLEGEECKVL PDRKGWSCSS GNKVKTTRVT H
Characteristics:	Fully biologically active when compared to standard. The biological activity is determined by its ability to enhance neurite outgrowth of E16-E18 rat embryonic cortical neurons. rHuTAFA-2, immobilized at 6-24 µg/mL on a 96 well plate, is able to significantly enhance neurite outgrowth.
Purity:	> 95 % by SDS-PAGE and HPLC analyses.
Sterility:	0.2 µm filtered
Endotoxin Level:	< 1 EU/µg of rHuTAFA-2 as determined by LAL method.

Target Details

Target:	FAM19A2
Alternative Name:	TAFA-2/FAM19A2 (FAM19A2 Products)

Target Details

Background:	TAFA-2 also named FAM19A2 belongs to the TAFA family of chemokinelike proteins. Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA1 to 4 contain 10 regularly spaced cysteine residues. Human TAFA2 is 97 % aa identical to mouse TAFA2. TAFA2 expression can be detected in the central nervous system (CNS), colon, heart, lung, spleen, kidney, and thymus, but its expression in the CNS is 50 to 1000 fold higher than in other tissues. Within the CNS, TAFA2 expression is highest in the occipital and frontal cortex (3 to 10 fold more abundantly expressed than in other cortical regions) and medulla. The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. Synonyms: Chemokine-like protein TAFA-2, FAM19A2
Molecular Weight:	11.2 kDa, a single, non-glycosylated polypeptide chain containing 101 amino acids.

Application Details

Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Buffer:	Lyophilized from a 0.2 µm filtered concentrated solution in 2 x PBS, pH 7.4.
Handling Advice:	Avoid repeated freeze/thaw cycles.
Storage:	4 °C/-20 °C
Storage Comment:	This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C.